StatSure Diagnostic Systems, Inc. And Chembio Diagnostics, Inc. Agree To End Litigation And Enter Agreement To Commercialize HIV Barrel Technology

MEDFORD, N.Y. & FRAMINGHAM, Mass.--(BUSINESS WIRE)--StatSure Diagnostic Systems, Inc. (OTCBB:SSUR) and Chembio Diagnostics, Inc. (OTCBB:CEMI) announced today that they have entered into a series of agreements that provide Inverness Medical Innovations, Inc. (AMEX:IMA) with exclusive worldwide marketing rights to Chembio’s FDA-cleared, point of care, rapid, SURE CHECK® HIV 1/2 product for the detection of HIV 1 & 2 antibodies. This test utilizes StatSure’s patented barrel technology, designed to provide convenient, safe, accurate and integrated single-use, rapid HIV antibody screening, and to minimize exposure to infectious agents; it will be exclusively manufactured by Chembio for Inverness’ distribution.

Back to news